<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.worldpharmaceuticals.net/wp-content/uploads/sites/12/2025/12/PT-30-12-2025-shutterstock_2383470841-425x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="425" height="241" original-src="https://imageproxy.pbkrs.com/https://www.worldpharmaceuticals.net/wp-content/uploads/sites/12/2025/12/PT-30-12-2025-shutterstock_2383470841-425x241.jpg"/>
                                    
                                    <figcaption>J&amp;J anticipates earnings dilution in the fourth quarter of 2025 and into 2026. Credit: Skorzewiak/Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                                                   
<p>Johnson &amp; Johnson (J&amp;J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash.</p>



<p>This move brings Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform to J&amp;J’s oncology portfolio, supporting the development of oral, targeted therapies for several solid tumours, including prostate cancer.</p>



<p>The acquisition includes HLD-0915, a clinical-stage, once-daily oral therapy for prostate cancer. This therapy utilises the RIPTAC platform for precision targeting of cancer cells, aiming to address resistance mechanisms.</p><div>
    <div>
        <div>
        <img src="https://imageproxy.pbkrs.com/https://hubspot-pmisites.pantheonsite.io/techmonitor/wp-content/themes/goodlife-wp-B2B/assets/images/icons/Module.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="130" height="183" original-src="https://imageproxy.pbkrs.com/https://hubspot-pmisites.pantheonsite.io/techmonitor/wp-content/themes/goodlife-wp-B2B/assets/images/icons/Module.png"/>
        </div>
        <div>
            <span class="gdm-company-profile-unit__form-excerpt gdm-btmi">Free Sample</span>
            <h3>Download sample pages of selected reports</h3>
            <p>
                Explore a selection of report samples we have handpicked for you. Get a preview of the insights inside. Download your free copy today.
            </p>
            <div>
                
                
            </div>
        </div>
    </div>
</div>



<p>Additionally, the deal adds early-stage candidates for breast, lung, and other tumour types, using RIPTAC technology, to J&amp;J’s pipeline.</p>



<p>The company indicated that this platform could potentially enable the development of additional targeted therapies beyond oncology.</p>



<p>With the deal closing in 2025, J&amp;J anticipates earnings dilution in the fourth quarter of 2025 and into 2026.</p>



<p>The total impact on adjusted earnings per share is expected to be around $0.20, divided equally between 2025 and 2026, reflecting charges related to Halda employee equity, financing, and integration costs.</p>



<p>J&amp;J innovative medicine worldwide chairman and executive vice president Jennifer Taubert said: “This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines.</p>



<p>“We are excited to formally welcome the talented Halda team to J&amp;J and look forward to working together to achieve our shared goal of eliminating cancer.”</p>



<p>J&amp;J innovative medicine R&amp;D executive vice-president John Reed said: “Now that we have finalised this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates and harnessing the powerful RIPTAC platform to discover more molecules in oncology and beyond.”</p>



<p>In November 2025, J&amp;J signed a definitive agreement for the acquisition of Halda.</p>
                        
                        <section>
                                <h3>Unlock up to 35% savings on GlobalData reports</h3>
                                <p>Use the code at checkout in the report store</p>
                                <ul>
                                    <li>
                                        <div>
                                            <h3>20% OFF</h3>
                                            <p>Buy 2 reports</p>
                                        </div>
                                        <div>
                                            <p>Use code:</p>
                                            <h4>Bundle20</h4>
                                        </div>
                                    </li>
                                    <li>
                                        <div>
                                            <h3>25% OFF</h3>
                                            <p>Buy 3 reports</p>
                                        </div>
                                        <div>
                                            <p>Use code:</p>
                                            <h4>Bundle25</h4>
                                        </div>
                                    </li>
                                    <li>
                                        <div>
                                            <h3>30% OFF</h3>
                                            <p>Buy 4 reports</p>
                                        </div>
                                        <div>
                                            <p>Use code:</p>
                                            <h4>Bundle30</h4>
                                        </div>
                                    </li>
                                    <li>
                                        <div>
                                            <h3>35% OFF</h3>
                                            <p>Buy 5+ reports</p>
                                        </div>
                                        <div>
                                            <p>Use code:</p>
                                            <h4>Bundle35</h4>
                                        </div>
                                    </li>
                                </ul>
                                <p>Valid on all reports priced $995 and above. Cannot be combined with other offers.</p>
                                <ul>
                             
                            </ul>

                                <section>
                                    <h4>
                                        Still deciding what will work best for your business?
                                    </h4>
                                    <p>Ask our experts for help.</p>
                                  
                                     Enquire before buying
                                </section>
                               
                               
                            </section>

<p>Johnson & Johnson (J&J) has acquired Halda Therapeutics for $3.05 billion in cash, enhancing its oncology portfolio with Halda's Regulated Induced Proximity Targeting Chimera (RIPTAC) platform. This acquisition includes HLD-0915, a clinical-stage oral therapy for prostate cancer, and early-stage candidates for other tumors. J&J expects earnings dilution of approximately $0.20 per share in Q4 2025 and into 2026 due to integration costs. J&J's executives emphasize the strategic importance of this acquisition in advancing cancer treatment.</p>

Johnson & Johnson acquires Halda Therapeutics for $3.05bn